Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	2/23/1987
Gender:	Female
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

CYP2B6

ARUP test code 3004310

2B6 Specimen	Whole Blood
CYP2B6 Genotype	Neg/Neg
CYP2B6 Phenotype	Normal
2B6 Interpretation	See Note The following CYP2B6 alleles were detected: Neg/Neg. This result predicts the normal metabolizer phenotype. Recommendation: Guidelines for gene-based dosing are published by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and other organizations. See https://www.pharmgkb.org This result has been reviewed and approved by [redacted]

H=High, L=Low, *=Abnormal, C=Critical

BACKGROUND INFORMATION FOR CYP2B6:
CHARACTERISTICS: The cytochrome P450 (CYP) isozyme 2B6 is involved in the metabolism of many drugs. Variants in the gene that codes for CYP2B6 may influence pharmacokinetics of substrates and may predict or explain non-standard dose requirements, therapeutic failure, or adverse reactions.
Inheritance: Autosomal codominant
CAUSE: CYP2B6 gene variants affect enzyme function.
VARIANTS TESTED:
(Variants are numbered according to the following transcripts: CYP2B6 NM_000767).

Negative: No variants detected is predictive of the *1 functional alleles.

CYP2B6*4: rs2279343, c.785A>G
CYP2B6*6: rs3745274, c.516G>T; rs2279343, c.785A>G
CYP2B6*7: rs3745274, c.516G>T; rs2279343, c.785A>G; rs3211371, c.1459C>T
CYP2B6*9: rs3745274, c.516G>T
CYP2B6*18: rs28399499, c.983T>C
CYP2B6*22: rs34223104, c.-82T>C
CYP2B6*36: rs34223104, c.-82T>C; rs3745274, c.516G>T; rs2279343, c.785A>G

CLINICAL SENSITVITY: Drug-dependent.
METHODOLOGY: Polymerase chain reaction (PCR) and fluorescence monitoring
ANALYTICAL SENSITIVITY AND SPECIFICITY: Greater than 99 percent
LIMITATIONS: Only the targeted CYP2B6 variants will be detected by this test, and assumptions about phase and content are made to assign alleles. Publicly available sources such as the www.pharmvar.org or www.pharmgkb.org provide guidance on phenotype predictions and allele frequencies. Diagnostic errors can occur due to rare sequence variations. Risk of therapeutic failure or adverse reactions with CYP2B6 substrates may be affected by genetic and non-genetic factors that are not detected by this test. This result does not replace the need for therapeutic drug or clinical monitoring.

Please note the information contained in this report does not contain medication recommendations and should not be interpreted as recommending any specific medications. Any dosage adjustments or other changes to medications should be evaluated in consultation with a medical provider.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
2B6 Specimen	22-055-103139	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CYP2B6 Genotype	22-055-103139	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CYP2B6 Phenotype	22-055-103139	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
2B6 Interpretation	22-055-103139	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical